# The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

> **NCT03444376** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** GX-188E
- **DRUG:** KEYTRUDA®

## Key facts

- **NCT ID:** NCT03444376
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2022-04-29
- **Final completion:** 2023-12-21
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444376, "The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03444376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*